781 related articles for article (PubMed ID: 24355761)
1. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
Vanden Broeck L; Callaerts P; Dermaut B
Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
[TBL] [Abstract][Full Text] [Related]
2. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R; Neumann M
Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052
[TBL] [Abstract][Full Text] [Related]
3. Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.
Root J; Merino P; Nuckols A; Johnson M; Kukar T
Neurobiol Dis; 2021 Jul; 154():105360. PubMed ID: 33812000
[TBL] [Abstract][Full Text] [Related]
4. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
Jovičić A; Paul JW; Gitler AD
J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
[TBL] [Abstract][Full Text] [Related]
5. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
Prudlo J
Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
[TBL] [Abstract][Full Text] [Related]
6. Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis.
van der Zee J; Dillen L; Baradaran-Heravi Y; Gossye H; Koçoğlu C; Cuyt I; Dermaut B; Sieben A; Baets J; De Jonghe P; Vandenberghe R; De Deyn P; Cras P; Engelborghs S; Van Broeckhoven C;
Neurobiol Dis; 2021 Aug; 156():105421. PubMed ID: 34118419
[TBL] [Abstract][Full Text] [Related]
7. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
Hayes LR; Kalab P
Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of amyotrophic lateral sclerosis.
Liscic RM; Breljak D
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):370-2. PubMed ID: 20655970
[TBL] [Abstract][Full Text] [Related]
9. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R
Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281
[TBL] [Abstract][Full Text] [Related]
10. The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders.
Gascon E; Gao FB
J Neurogenet; 2014; 28(1-2):30-40. PubMed ID: 24506814
[TBL] [Abstract][Full Text] [Related]
11. Phase to Phase with TDP-43.
Sun Y; Chakrabartty A
Biochemistry; 2017 Feb; 56(6):809-823. PubMed ID: 28112502
[TBL] [Abstract][Full Text] [Related]
12. Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice.
Ke YD; van Hummel A; Au C; Chan G; Lee WS; van der Hoven J; Przybyla M; Deng Y; Sabale M; Morey N; Bertz J; Feiten A; Ippati S; Stevens CH; Yang S; Gladbach A; Haass NK; Kril JJ; Blair IP; Delerue F; Ittner LM
Neuron; 2024 Apr; 112(8):1249-1264.e8. PubMed ID: 38366598
[TBL] [Abstract][Full Text] [Related]
13. Distribution of ubiquilin 2 and TDP-43 aggregates throughout the CNS in UBQLN2 p.T487I-linked amyotrophic lateral sclerosis and frontotemporal dementia.
Nementzik LR; Thumbadoo KM; Murray HC; Gordon D; Yang S; Blair IP; Turner C; Faull RLM; Curtis MA; McLean C; Nicholson GA; Swanson MEV; Scotter EL
Brain Pathol; 2024 May; 34(3):e13230. PubMed ID: 38115557
[TBL] [Abstract][Full Text] [Related]
14. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia.
Sidibé H; Khalfallah Y; Xiao S; Gómez NB; Fakim H; Tank EMH; Di Tomasso G; Bareke E; Aulas A; McKeever PM; Melamed Z; Destroimaisons L; Deshaies JE; Zinman L; Parker JA; Legault P; Tétreault M; Barmada SJ; Robertson J; Vande Velde C
Brain; 2021 Dec; 144(11):3461-3476. PubMed ID: 34115105
[TBL] [Abstract][Full Text] [Related]
15. TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Bright F; Chan G; van Hummel A; Ittner LM; Ke YD
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360544
[TBL] [Abstract][Full Text] [Related]
16. [Neurodegenerative disorders and TDP-43].
Nonaka T; Inukai Y; Arai T; Hasegawa M
Brain Nerve; 2009 Feb; 61(2):161-6. PubMed ID: 19235466
[TBL] [Abstract][Full Text] [Related]
17. TAR DNA-binding protein 43 in neurodegenerative disease.
Chen-Plotkin AS; Lee VM; Trojanowski JQ
Nat Rev Neurol; 2010 Apr; 6(4):211-20. PubMed ID: 20234357
[TBL] [Abstract][Full Text] [Related]
18. TDP-43 is a ubiquitylation substrate of the SCF
Rayner SL; Yang S; Farrawell NE; Jagaraj CJ; Cheng F; Davidson JM; Luu L; Redondo AG; Rábano A; Borrego-Hernández D; Atkin JD; Morsch M; Blair IP; Yerbury JJ; Chung R; Lee A
Neurobiol Dis; 2022 Jun; 167():105673. PubMed ID: 35231559
[TBL] [Abstract][Full Text] [Related]
19. Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons.
Liu EY; Russ J; Cali CP; Phan JM; Amlie-Wolf A; Lee EB
Cell Rep; 2019 Apr; 27(5):1409-1421.e6. PubMed ID: 31042469
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of ALS and FTD: implications for translational studies.
Liščić RM
Arh Hig Rada Toksikol; 2015 Dec; 66(4):285-90. PubMed ID: 26751860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
